Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Thyroid Neoplasms × sacituzumab govitecan × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 36 Triple Negative Breast Neoplasms 28 Carcinoma, Non-Small-Cell Lung 10 Urinary Bladder Neoplasms 9 Carcinoma, Transitional Cell 9 Neoplasm Metastasis 8 Lung Neoplasms 5 Endometrial Neoplasms 4 Brain Neoplasms 4 Small Cell Lung Carcinoma 3 Glioblastoma 3 Uterine Cervical Neoplasms 2 Salivary Gland Neoplasms 2 Pancreatic Neoplasms 2 Ovarian Neoplasms 2 Esophageal Neoplasms 2 Colorectal Neoplasms 2 Carcinoma, Ovarian Epithelial 2 Advanced Breast Cancer 2 Uterine Neoplasms 1 Urothelial Bladder Carcinoma 1 Triple Negative Locally Advanced Non-resectable Breast Cancer 1 Thyroid Neoplasms 1 Thyroid Carcinoma, Anaplastic 1 Stomach Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Solid Tumor 1 Recurrence 1 Prostatic Neoplasms, Castration-Resistant 1 Prostatic Neoplasms 1

Interventions

Iodine-131 19 lenvatinib 15 Sorafenib 11 trametinib 10 Thyrotropin Alfa 10 Magnetic Resonance Spectroscopy 10 pembrolizumab 9 Thyroidectomy 9 Surgical Procedures, Operative 9 vandetanib 8 dabrafenib 8 Thyroxine 8 Paclitaxel 8 selpercatinib 7 anlotinib 6 Sunitinib 6 Everolimus 6 pazopanib 5 cabozantinib 5 Vemurafenib 5 Triiodothyronine 5 Saline Solution 5 Nivolumab 5 Fluorodeoxyglucose F18 5 Cyclophosphamide 5 Biopsy, Fine-Needle 5 Radiofrequency Ablation 4 Iodine-124 4 Docetaxel 4 Dexmedetomidine 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06923826 2025-07-25

TROP2

National University Hospital, Singapore

Phase 2 Recruiting

Salivary Gland Neoplasms, Thyroid Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡